دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Translating immuno-onco-microbiome-based therapeutics: precision bugs for immune checkpoint drugs!
V. Subbiah 1* & S. Pant
doi : 10.1016/j.annonc.2023.03.002
Volume 34, Issue 6, June 2023, Pages 503-506
Next generation radiotheranostics promoting precision medicine
K. L. Pomykala1 , B. A. Hadaschik2 , O. Sartor 3 , S. Gillessen 4,5,6 , C. J. Sweeney 7,8 , T. Maughan 9 , M. S. Hofman 10,11 & K. Herrmann
doi : 10.1016/j.annonc.2023.03.001
Volume 34, Issue 6, June 2023, Pages 507-519
First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial)
A. Spreafico 1,2* , A. A. Heirali3 , D. V. Araujo 1,4 , T. J. Tan 1,5 , M. Oliva 1,6,7 , P. H. H. Schneeberger 3,8,9 , B. Chen 10 , M. K. Wong 11 , L.-A. Stayner 1 , A. R. Hansen1 , S. D. Saibil 1 , B. X. Wang 2 , K. Cochrane 12 , K. Sherriff 12 , E. Allen-Vercoe12 , W. Xu 10 , L. L. Siu 1,2 & B. Coburn
doi : 10.1016/j.annonc.2023.02.011
Volume 34, Issue 6, June 2023, Pages 520-530
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial
O. Gluz 1,2,3* , S. Kuemmel 1,4,5 , U. Nitz 1,2 , M. Braun 6 , K. Lüdtke-Heckenkamp7 , R. von Schumann2 , M. Darsow8,9 , H. Forstbauer 10 , J. Potenberg 11 , C. Uleer 12 , E. M. Grischke 13 , B. Aktas 14,15 , C. Schumacher 16 , C. zu Eulenburg1,17 , R. Kates 1 , K. J?zwiak 18 , M. Graeser 1,2,19 , R. Wuerstlein 1,20 , R. Baehner21 , M. Christgen22 , H. H. Kreipe22 & N. Harbeck
doi : 10.1016/j.annonc.2023.04.002
Volume 34, Issue 6, June 2023, Pages 531-542
Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments
J. Ros1,2,3 , J. Matito 3y, G. Villacampa 3,4y, R. Comas 3 , A. Garcia 3 , G. Martini 2 , I. Baraibar 1,3 , N. Saoudi 1,3 , F. Salvà 1,3 , ?. Martin 1 , M. Antista 5 , R. Toledo3 , E. Martinelli 2 , F. Pietrantonio 5 , A. Boccaccino 6 , C. Cremolini 6 , R. Dientsmann3 , J. Tabernero 1,3 , A. Vivancos 3 & E. Elez
doi : 10.1016/j.annonc.2023.02.016
Volume 34, Issue 6, June 2023, Pages 543-552
Neoadjuvant radiochemotherapy and perioperative chemotherapy do not represent a standard at the same priority level for esophageal adenocarcinomas (with regard to ‘Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up’)
. Cellini 1,2 *, S. Manfrida 1 , M. A. Gambacorta1,2 & V. Valentini 1,2
doi : 10.1016/j.annonc.2023.03.003
Volume 34, Issue 6, June 2023, Pages 553-554
Reply to the Letter to the Editor ‘Neoadjuvant radiochemotherapy and perioperative chemotherapy does not represent a standard at same priority level for oesophageal adenocarcinomas (in regard to “Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up�)’ by Cellini et al.
R. Obermannov? 1 & E. C. Smyth2 , on behalf of the ESMO Guidelines Committee
doi : 10.1016/j.annonc.2023.03.004
Volume 34, Issue 6, June 2023, Pages 554-555
Second-line FOLFOX is not the standard of care for all patients with advanced biliary tract cancer—a commentary from the Young International Society of Geriatric Oncology
G. Liposits 1,2,3 *, S. P. Arora4 , N. M. L. Battisti 5,6 , E. Soto-Perez-de-Celis 7 , K. P. Loh8 & G. R. Williams
doi : 10.1016/j.annonc.2023.02.007
Volume 34, Issue 6, June 2023, Pages 555-556
Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents
K. Fizazi 1 & S. Gillessen 2 , on behalf of the ESMO Guidelines Committee
doi : 10.1016/j.annonc.2023.02.015
Volume 34, Issue 6, June 2023, Pages 557-563
